Login to Your Account



Antegren Renamed, Approved; 'Blockbuster,' But How Soon?

By Randall Osborne


Monday, November 29, 2004
As many predicted, the FDA approved Biogen Idec Inc.'s multiple sclerosis drug Tysabri (formerly known as Antegren) as a combination and monotherapy for relapsing forms of the disease, but the company and partner Elan Corp. plc did not disclose pricing for the would-be blockbuster. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription